“…These include inhibition of Janus kinase (JAK) 3, with a resulting effect on platelet-derived growth factor, the modulation of transforming growth factor (TGF)-b 1 and of agents influencing vascular endothelial growth factor all in rat transplant models [18,19]. Studies in the murine model using pirfenidone, which also affects TGF-b 1 , have demonstrated a delay in the onset, as well as a reduction in the severity, of OB when administered early in the post-transplant period, suggesting that pirfenidone may be a candidate drug to be evaluated in human subjects [20].…”